$Checkpoint Inhibitor Refractory Cancer Market Global Report 2026 Market Report Infographic Image$

Published : April 2026

Pages : 250

Format : PDF

Delivery Time : 2-3 Business Days

Report Price : $4490.00

Checkpoint Inhibitor Refractory Cancer Market Report 2026

Name: Checkpoint Inhibitor Refractory Cancer Market Report 2026
Brand: The Business Research Company
Price: 4490.00 USD
Availability: InStock

Global Outlook – By Therapy (Immune Checkpoint Inhibitors, Combination Therapies, Targeted Therapies), By Cancer Type (Non-Small Cell Lung Cancer (NSCLC), Melanoma, Renal Cell Carcinoma (RCC), Head And Neck Squamous Cell Carcinoma (HNSCC), Urothelial Carcinoma, Triple-Negative Breast Cancer (TNBC), Colorectal Cancer, Other Cancer Types), By Mechanism Of Action (Programmed Cell Death Protein (PD)-1 Inhibitors, Programmed Death-Ligand (PD)-L1 Inhibitors, Cytotoxic T-Lymphocyte–Associated Protein (CTLA)-4 Inhibitors, Other Mechanism Of Actions), By Administration Route (Intravenous (IV), Oral), By End-User (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies) – Market Size, Trends, Strategies, and Forecast to 2035

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

Purchase This Report Download Sample PDF

Item added to cart!

Checkpoint Inhibitor Refractory Cancer Market Overview

• Checkpoint Inhibitor Refractory Cancer market size has reached to $36.69 billion in 2025

• Expected to grow to $63.02 billion in 2030 at a compound annual growth rate (CAGR) of 11.4%

• Growth Driver: Rising Incidence Of Cancer Driving The Growth Of The Market Due To An Aging Population

• Market Trend: Technological Advancements And Early-Phase Clinical Data In Checkpoint Inhibitor Refractory Cancer Market

• North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Checkpoint Inhibitor Refractory Cancer Market?

Checkpoint inhibitor refractory cancer is a type of cancer that fails to respond to immune checkpoint inhibitors such as PD-1, PD-L1, or CTLA-4 blockers. This can occur as primary resistance, where there is no initial response, or as acquired resistance, where the cancer progresses after an initial benefit. Managing these cases often requires alternative treatments, such as combination immunotherapy, targeted agents, or novel experimental strategies.

The main therapies for checkpoint inhibitor refractory cancer include immune checkpoint inhibitors, combination therapies, and targeted therapies. Immune checkpoint inhibitors are medicines that help the immune system recognize and attack cancer cells by blocking proteins that stop immune cells from working properly. It is used for various cancer types such as non-small cell lung cancer (NSCLC), melanoma, renal cell carcinoma (RCC), head and neck squamous cell carcinoma (HNSCC), urothelial carcinoma, triple-negative breast cancer (TNBC), colorectal cancer, and others. The various mechanisms of action include programmed cell death protein (PD)-1 inhibitors, programmed death-ligand (PD)-l1 inhibitors, cytotoxic T-lymphocyte–associated protein (CTLA)-4 inhibitors, and others. and the various routes of administration involved are intravenous (IV) and oral. It is used by several end users, including hospital pharmacies, retail pharmacies, and online pharmacies.

$Checkpoint Inhibitor Refractory Cancer Market Global Report 2026 Market Report bar graph$

What Is The Checkpoint Inhibitor Refractory Cancer Market Size and Share 2026?

The checkpoint inhibitor refractory cancer market size has grown rapidly in recent years. It will grow from $36.69 billion in 2025 to $40.97 billion in 2026 at a compound annual growth rate (CAGR) of 11.7%. The growth in the historic period can be attributed to increasing use of immune checkpoint inhibitors in oncology, rising incidence of advanced-stage cancers, limited treatment options after immunotherapy failure, growing oncology drug approvals, expansion of cancer treatment centers.

What Is The Checkpoint Inhibitor Refractory Cancer Market Growth Forecast?

The checkpoint inhibitor refractory cancer market size is expected to see rapid growth in the next few years. It will grow to $63.02 billion in 2030 at a compound annual growth rate (CAGR) of 11.4%. The growth in the forecast period can be attributed to development of next-generation immunotherapies, increasing investment in combination and targeted therapies, rising precision oncology adoption, expansion of global oncology clinical trials, growing focus on personalized cancer treatment strategies. Major trends in the forecast period include rising focus on overcoming primary and acquired resistance to checkpoint inhibitors, increasing adoption of combination immunotherapy regimens, growth in targeted therapies for immunotherapy-refractory cancers, expansion of clinical trials for novel and experimental therapies, rising demand for biomarker-based patient stratification.

Book your 30 minutes free consultation with our research experts

Global Checkpoint Inhibitor Refractory Cancer Market Segmentation

1) By Therapy: Immune Checkpoint Inhibitors, Combination Therapies, Targeted Therapies

2) By Cancer Type: Non-Small Cell Lung Cancer (NSCLC), Melanoma, Renal Cell Carcinoma (RCC), Head And Neck Squamous Cell Carcinoma (HNSCC), Urothelial Carcinoma, Triple-Negative Breast Cancer (TNBC), Colorectal Cancer, Other Cancer Types

3) By Mechanism Of Action: Programmed Cell Death Protein (PD)-1 Inhibitors, Programmed Death-Ligand (PD)-L1 Inhibitors, Cytotoxic T-Lymphocyte–Associated Protein (CTLA)-4 Inhibitors, Other Mechanism Of Actions

4) By Administration Route: Intravenous (IV), Oral

5) By End-User: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

Subsegments:

1) By Immune Checkpoint Inhibitors (ICIs): PD-1 Inhibitors, PD-L1 Inhibitors, CTLA-4 Inhibitors

2) By Combination Therapies: Checkpoint Inhibitor + Chemotherapy, Checkpoint Inhibitor + Targeted Therapy, Checkpoint Inhibitor + Other Immunotherapies, Dual Checkpoint Inhibitor Combinations

3) By Targeted Therapies: Tyrosine Kinase Inhibitors (TKIs), Monoclonal Antibodies Targeting Specific Cancer Markers

What Is The Driver Of The Checkpoint Inhibitor Refractory Cancer Market?

The rising incidence of cancer is expected to propel the growth of the checkpoint inhibitor refractory cancer market going forward. Cancer refers to a disease characterized by the uncontrolled division and growth of abnormal cells in the body. The rising incidence of cancer is mainly due to an aging population, as longer life expectancy increases the likelihood of developing cancer over time. Recognizing checkpoint inhibitor refractory cancer is valuable in cancer management, as it enables early detection of treatment resistance, guiding clinicians to promptly modify therapy and pursue alternative approaches that may enhance patient outcomes. For instance, in February 2025, according to the United Nations, a US-based intergovernmental organization, an estimated 2.3 million new breast cancer cases were diagnosed in 2022, resulting in 670,000 deaths, and global projections indicate a 38% increase in cases and a 68% rise in annual deaths by 2050. Therefore, the rising incidence of cancer is driving the growth of the checkpoint inhibitor refractory cancer industry.

Key Players In The Global Checkpoint Inhibitor Refractory Cancer Market

Major companies operating in the checkpoint inhibitor refractory cancer market are Pfizer Inc., Johnson & Johnson Private Limited, Merck & Co. Inc., AbbVie Inc., Novartis International AG, Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca PLC, GlaxoSmithKline Plc, Eli Lilly and Company, Gilead Sciences Inc., Amgen Inc., Regeneron Pharmaceuticals Inc., Eisai Co. Ltd., Exelixis Inc., Exicure Inc., ImmunityBio Inc., ENB Therapeutics Inc., Kartos Therapeutics Inc., Pliant Therapeutics Inc.

Global Checkpoint Inhibitor Refractory Cancer Market Trends and Insights

Major companies operating in the checkpoint inhibitor refractory cancer market are focusing on developing innovative products, such as dual selective inhibitors, to reduce the likelihood of drug resistance by targeting two critical pathways involved in disease progression. Dual selective inhibitors are compounds that block two distinct biological targets or pathways at the same time while limiting impact on other unrelated pathways. For instance, in March 2025, Pliant Therapeutics Inc., a US-based clinical-stage biopharmaceutical company, announced Interim Phase 1 Data for PLN-101095 in Patients with Immune Checkpoint Inhibitor-Refractory Advanced Solid Tumors. Pliant Therapeutics’ interim Phase 1 data for PLN-101095 in patients with immune checkpoint inhibitor–refractory advanced solid tumors demonstrated promising early activity and a manageable safety profile. At the highest tested dose of 1,000 mg twice daily combined with pembrolizumab, the trial reported a 50% objective response rate, including confirmed partial responses in patients with non-small cell lung cancer, cholangiocarcinoma, and melanoma, showing significant tumor reductions. PLN-101095 was generally well tolerated, with most treatment-emergent adverse events being mild to moderate. The study is ongoing, with higher-dose cohorts currently enrolling and additional data expected by the end of 2025.

Need data on a specific region in this market?

Request Regional Data

What Are Latest Mergers And Acquisitions In The Checkpoint Inhibitor Refractory Cancer Market?

In October 2023, Bristol-Myers Squibb Company, a US-based pharmaceutical industry company, acquired Mirati Therapeutics Inc. for an undisclosed amount. Through this acquisition, Bristol Myers Squibb aims to strengthen and diversify its oncology portfolio by integrating Mirati’s innovative cancer therapies and clinical-stage assets, particularly targeting KRAS-mutated cancers and checkpoint inhibitor refractory cancers. Mirati Therapeutics Inc. is a US-based provider of therapies specifically designed for checkpoint inhibitor refractory (resistant) cancers.

Regional Insights

North America was the largest region in the checkpoint inhibitor refractory cancer market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Checkpoint Inhibitor Refractory Cancer Market?

The checkpoint inhibitor refractory cancer market includes revenues earned by entities by providing services such as diagnostic and biomarker services, clinical trials and research services, specialized oncology treatment services, and patient support and consulting services. The market value includes the value of related goods sold by the service provider or included within the service offering. The checkpoint inhibitor refractory cancer market consists of sales of tumor-infiltrating lymphocyte (TIL) therapy kits, genomic sequencing panels, tumor organoids, drug discovery tools, and bispecific antibodies. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Checkpoint Inhibitor Refractory Cancer Market Report 2026?

The checkpoint inhibitor refractory cancer market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the checkpoint inhibitor refractory cancer industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.

Author : Abhilash Pyata

Checkpoint Inhibitor Refractory Cancer Market Report Forecast Analysis

Report Attribute	Details
Market Size Value In 2026	$40.97 billion
Revenue Forecast In 2035	$63.02 billion
Growth Rate	CAGR of 11.7% from 2026 to 2035
Base Year For Estimation	2025
Actual Estimates/Historical Data	2020-2025
Forecast Period	2026 - 2030 - 2035
Market Representation	Revenue in USD Billion and CAGR from 2026 to 2035
Segments Covered	Therapy, Cancer Type, Mechanism Of Action, Administration Route, End-User
Regional Scope	Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Country Scope	The countries covered in the report are Australia, Brazil, China, France, Germany, India, ...
Key Companies Profiled	Pfizer Inc., Johnson & Johnson Private Limited, Merck & Co. Inc., AbbVie Inc., Novartis International AG, Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca PLC, GlaxoSmithKline Plc, Eli Lilly and Company, Gilead Sciences Inc., Amgen Inc., Regeneron
Customization Scope	Request for Customization
Pricing And Purchase Options	Explore Purchase Options

1. Executive Summary

1.1. Key Market Insights (2020-2035)

1.2. Visual Dashboard: Market Size, Growth Rate, Hotspots

1.3. Major Factors Driving the Market

1.4. Top Three Trends Shaping the Market

2. Checkpoint Inhibitor Refractory Cancer Market Characteristics

2.1. Market Definition & Scope

2.2. Market Segmentations

2.3. Overview of Key Products and Services

2.4. Global Checkpoint Inhibitor Refractory Cancer Market Attractiveness Scoring And Analysis

2.4.1. Overview of Market Attractiveness Framework

2.4.2. Quantitative Scoring Methodology

2.4.3. Factor-Wise Evaluation

Growth Potential Analysis, Competitive Dynamics Assessment, Strategic Fit Assessment And Risk Profile Evaluation

2.4.4. Market Attractiveness Scoring and Interpretation

2.4.5. Strategic Implications and Recommendations

3. Checkpoint Inhibitor Refractory Cancer Market Supply Chain Analysis

3.1. Overview of the Supply Chain and Ecosystem

3.2. List Of Key Raw Materials, Resources & Suppliers

3.3. List Of Major Distributors and Channel Partners

3.4. List Of Major End Users

4. Global Checkpoint Inhibitor Refractory Cancer Market Trends And Strategies

4.1. Key Technologies & Future Trends

4.1.1 Biotechnology, Genomics & Precision Medicine

4.1.2 Artificial Intelligence & Autonomous Intelligence

4.1.3 Digitalization, Cloud, Big Data & Cybersecurity

4.1.4 Industry 4.0 & Intelligent Manufacturing

4.1.5 Internet Of Things (Iot), Smart Infrastructure & Connected Ecosystems

4.2. Major Trends

4.2.1 Rising Focus On Overcoming Primary And Acquired Resistance To Checkpoint Inhibitors

4.2.2 Increasing Adoption Of Combination Immunotherapy Regimens

4.2.3 Growth In Targeted Therapies For Immunotherapy-Refractory Cancers

4.2.4 Expansion Of Clinical Trials For Novel And Experimental Therapies

4.2.5 Rising Demand For Biomarker-Based Patient Stratification

5. Checkpoint Inhibitor Refractory Cancer Market Analysis Of End Use Industries

5.1 Hospital Pharmacies

5.2 Retail Pharmacies

5.3 Online Pharmacies

5.4 Specialty Oncology Centers

5.5 Cancer Research Institutes

6. Checkpoint Inhibitor Refractory Cancer Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, Supply Chain Impact from Tariff War & Trade Protectionism, And Covid And Recovery On The Market

7. Global Checkpoint Inhibitor Refractory Cancer Strategic Analysis Framework, Current Market Size, Market Comparisons And Growth Rate Analysis

7.1. Global Checkpoint Inhibitor Refractory Cancer PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)

7.2. Global Checkpoint Inhibitor Refractory Cancer Market Size, Comparisons And Growth Rate Analysis

7.3. Global Checkpoint Inhibitor Refractory Cancer Historic Market Size and Growth, 2020 - 2025, Value ($ Billion)

7.4. Global Checkpoint Inhibitor Refractory Cancer Forecast Market Size and Growth, 2025 - 2030, 2035F, Value ($ Billion)

8. Global Checkpoint Inhibitor Refractory Cancer Total Addressable Market (TAM) Analysis for the Market

8.1. Definition and Scope of Total Addressable Market (TAM)

8.2. Methodology and Assumptions

8.3. Global Total Addressable Market (TAM) Estimation

8.4. TAM vs. Current Market Size Analysis

8.5. Strategic Insights and Growth Opportunities from TAM Analysis

9. Checkpoint Inhibitor Refractory Cancer Market Segmentation

9.1. Global Checkpoint Inhibitor Refractory Cancer Market, Segmentation By Therapy, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Immune Checkpoint Inhibitors, Combination Therapies, Targeted Therapies

9.2. Global Checkpoint Inhibitor Refractory Cancer Market, Segmentation By Cancer Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Non-Small Cell Lung Cancer (NSCLC), Melanoma, Renal Cell Carcinoma (RCC), Head And Neck Squamous Cell Carcinoma (HNSCC), Urothelial Carcinoma, Triple-Negative Breast Cancer (TNBC), Colorectal Cancer, Other Cancer Types

9.3. Global Checkpoint Inhibitor Refractory Cancer Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Programmed Cell Death Protein (PD)-1 Inhibitors, Programmed Death-Ligand (PD)-L1 Inhibitors, Cytotoxic T-Lymphocyte–Associated Protein (CTLA)-4 Inhibitors, Other Mechanism Of Actions

9.4. Global Checkpoint Inhibitor Refractory Cancer Market, Segmentation By Administration Route, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Intravenous (IV), Oral

9.5. Global Checkpoint Inhibitor Refractory Cancer Market, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

9.6. Global Checkpoint Inhibitor Refractory Cancer Market, Sub-Segmentation Of Immune Checkpoint Inhibitors, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

PD-1 Inhibitors, PD-L1 Inhibitors, CTLA-4 Inhibitors

9.7. Global Checkpoint Inhibitor Refractory Cancer Market, Sub-Segmentation Of Combination Therapies, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Checkpoint Inhibitor + Chemotherapy, Checkpoint Inhibitor + Targeted Therapy, Checkpoint Inhibitor + Other Immunotherapies, Dual Checkpoint Inhibitor Combinations

9.8. Global Checkpoint Inhibitor Refractory Cancer Market, Sub-Segmentation Of Targeted Therapies, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Tyrosine Kinase Inhibitors (TKIs), Monoclonal Antibodies Targeting Specific Cancer Markers

10. Checkpoint Inhibitor Refractory Cancer Market Regional And Country Analysis

10.1. Global Checkpoint Inhibitor Refractory Cancer Market, Split By Region, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

10.2. Global Checkpoint Inhibitor Refractory Cancer Market, Split By Country, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

11. Asia-Pacific Checkpoint Inhibitor Refractory Cancer Market

11.1. Asia-Pacific Checkpoint Inhibitor Refractory Cancer Market Overview

Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

11.2. Asia-Pacific Checkpoint Inhibitor Refractory Cancer Market, Segmentation By Therapy, Segmentation By Cancer Type, Segmentation By Mechanism Of Action, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

12. China Checkpoint Inhibitor Refractory Cancer Market

12.1. China Checkpoint Inhibitor Refractory Cancer Market Overview

Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

12.2. China Checkpoint Inhibitor Refractory Cancer Market, Segmentation By Therapy, Segmentation By Cancer Type, Segmentation By Mechanism Of Action, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

13. India Checkpoint Inhibitor Refractory Cancer Market

13.1. India Checkpoint Inhibitor Refractory Cancer Market, Segmentation By Therapy, Segmentation By Cancer Type, Segmentation By Mechanism Of Action, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

14. Japan Checkpoint Inhibitor Refractory Cancer Market

14.1. Japan Checkpoint Inhibitor Refractory Cancer Market Overview

14.2. Japan Checkpoint Inhibitor Refractory Cancer Market, Segmentation By Therapy, Segmentation By Cancer Type, Segmentation By Mechanism Of Action, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

15. Australia Checkpoint Inhibitor Refractory Cancer Market

15.1. Australia Checkpoint Inhibitor Refractory Cancer Market, Segmentation By Therapy, Segmentation By Cancer Type, Segmentation By Mechanism Of Action, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

16. Indonesia Checkpoint Inhibitor Refractory Cancer Market

16.1. Indonesia Checkpoint Inhibitor Refractory Cancer Market, Segmentation By Therapy, Segmentation By Cancer Type, Segmentation By Mechanism Of Action, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

17. South Korea Checkpoint Inhibitor Refractory Cancer Market

17.1. South Korea Checkpoint Inhibitor Refractory Cancer Market Overview

17.2. South Korea Checkpoint Inhibitor Refractory Cancer Market, Segmentation By Therapy, Segmentation By Cancer Type, Segmentation By Mechanism Of Action, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

18. Taiwan Checkpoint Inhibitor Refractory Cancer Market

18.1. Taiwan Checkpoint Inhibitor Refractory Cancer Market Overview

18.2. Taiwan Checkpoint Inhibitor Refractory Cancer Market, Segmentation By Therapy, Segmentation By Cancer Type, Segmentation By Mechanism Of Action, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

19. South East Asia Checkpoint Inhibitor Refractory Cancer Market

19.1. South East Asia Checkpoint Inhibitor Refractory Cancer Market Overview

19.2. South East Asia Checkpoint Inhibitor Refractory Cancer Market, Segmentation By Therapy, Segmentation By Cancer Type, Segmentation By Mechanism Of Action, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

20. Western Europe Checkpoint Inhibitor Refractory Cancer Market

20.1. Western Europe Checkpoint Inhibitor Refractory Cancer Market Overview

20.2. Western Europe Checkpoint Inhibitor Refractory Cancer Market, Segmentation By Therapy, Segmentation By Cancer Type, Segmentation By Mechanism Of Action, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

21. UK Checkpoint Inhibitor Refractory Cancer Market

21.1. UK Checkpoint Inhibitor Refractory Cancer Market, Segmentation By Therapy, Segmentation By Cancer Type, Segmentation By Mechanism Of Action, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

22. Germany Checkpoint Inhibitor Refractory Cancer Market

22.1. Germany Checkpoint Inhibitor Refractory Cancer Market, Segmentation By Therapy, Segmentation By Cancer Type, Segmentation By Mechanism Of Action, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

23. France Checkpoint Inhibitor Refractory Cancer Market

23.1. France Checkpoint Inhibitor Refractory Cancer Market, Segmentation By Therapy, Segmentation By Cancer Type, Segmentation By Mechanism Of Action, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

24. Italy Checkpoint Inhibitor Refractory Cancer Market

24.1. Italy Checkpoint Inhibitor Refractory Cancer Market, Segmentation By Therapy, Segmentation By Cancer Type, Segmentation By Mechanism Of Action, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

25. Spain Checkpoint Inhibitor Refractory Cancer Market

25.1. Spain Checkpoint Inhibitor Refractory Cancer Market, Segmentation By Therapy, Segmentation By Cancer Type, Segmentation By Mechanism Of Action, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

26. Eastern Europe Checkpoint Inhibitor Refractory Cancer Market

26.1. Eastern Europe Checkpoint Inhibitor Refractory Cancer Market Overview

26.2. Eastern Europe Checkpoint Inhibitor Refractory Cancer Market, Segmentation By Therapy, Segmentation By Cancer Type, Segmentation By Mechanism Of Action, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

27. Russia Checkpoint Inhibitor Refractory Cancer Market

27.1. Russia Checkpoint Inhibitor Refractory Cancer Market, Segmentation By Therapy, Segmentation By Cancer Type, Segmentation By Mechanism Of Action, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

28. North America Checkpoint Inhibitor Refractory Cancer Market

28.1. North America Checkpoint Inhibitor Refractory Cancer Market Overview

28.2. North America Checkpoint Inhibitor Refractory Cancer Market, Segmentation By Therapy, Segmentation By Cancer Type, Segmentation By Mechanism Of Action, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

29. USA Checkpoint Inhibitor Refractory Cancer Market

29.1. USA Checkpoint Inhibitor Refractory Cancer Market Overview

29.2. USA Checkpoint Inhibitor Refractory Cancer Market, Segmentation By Therapy, Segmentation By Cancer Type, Segmentation By Mechanism Of Action, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

30. Canada Checkpoint Inhibitor Refractory Cancer Market

30.1. Canada Checkpoint Inhibitor Refractory Cancer Market Overview

30.2. Canada Checkpoint Inhibitor Refractory Cancer Market, Segmentation By Therapy, Segmentation By Cancer Type, Segmentation By Mechanism Of Action, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

31. South America Checkpoint Inhibitor Refractory Cancer Market

31.1. South America Checkpoint Inhibitor Refractory Cancer Market Overview

31.2. South America Checkpoint Inhibitor Refractory Cancer Market, Segmentation By Therapy, Segmentation By Cancer Type, Segmentation By Mechanism Of Action, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

32. Brazil Checkpoint Inhibitor Refractory Cancer Market

32.1. Brazil Checkpoint Inhibitor Refractory Cancer Market, Segmentation By Therapy, Segmentation By Cancer Type, Segmentation By Mechanism Of Action, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

33. Middle East Checkpoint Inhibitor Refractory Cancer Market

33.1. Middle East Checkpoint Inhibitor Refractory Cancer Market Overview

33.2. Middle East Checkpoint Inhibitor Refractory Cancer Market, Segmentation By Therapy, Segmentation By Cancer Type, Segmentation By Mechanism Of Action, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

34. Africa Checkpoint Inhibitor Refractory Cancer Market

34.1. Africa Checkpoint Inhibitor Refractory Cancer Market Overview

34.2. Africa Checkpoint Inhibitor Refractory Cancer Market, Segmentation By Therapy, Segmentation By Cancer Type, Segmentation By Mechanism Of Action, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

35. Checkpoint Inhibitor Refractory Cancer Market Regulatory and Investment Landscape

36. Checkpoint Inhibitor Refractory Cancer Market Competitive Landscape And Company Profiles

36.1. Checkpoint Inhibitor Refractory Cancer Market Competitive Landscape And Market Share 2024

36.1.1. Top 10 Companies (Ranked by revenue/share)

36.2. Checkpoint Inhibitor Refractory Cancer Market - Company Scoring Matrix

36.2.1. Market Revenues

36.2.2. Product Innovation Score

36.2.3. Brand Recognition

36.3. Checkpoint Inhibitor Refractory Cancer Market Company Profiles

36.3.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis

36.3.2. Johnson & Johnson Private Limited Overview, Products and Services, Strategy and Financial Analysis

36.3.3. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis

36.3.4. AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis

36.3.5. Novartis International AG Overview, Products and Services, Strategy and Financial Analysis

37. Checkpoint Inhibitor Refractory Cancer Market Other Major And Innovative Companies

Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca PLC, GlaxoSmithKline Plc, Eli Lilly and Company, Gilead Sciences Inc., Amgen Inc., Regeneron Pharmaceuticals Inc., Eisai Co. Ltd., Exelixis Inc., Exicure Inc., ImmunityBio Inc., ENB Therapeutics Inc., Kartos Therapeutics Inc., Pliant Therapeutics Inc.

38. Global Checkpoint Inhibitor Refractory Cancer Market Competitive Benchmarking And Dashboard

39. Key Mergers And Acquisitions In The Checkpoint Inhibitor Refractory Cancer Market

40. Checkpoint Inhibitor Refractory Cancer Market High Potential Countries, Segments and Strategies

40.1 Checkpoint Inhibitor Refractory Cancer Market In 2030 - Countries Offering Most New Opportunities

40.2 Checkpoint Inhibitor Refractory Cancer Market In 2030 - Segments Offering Most New Opportunities

40.3 Checkpoint Inhibitor Refractory Cancer Market In 2030 - Growth Strategies

40.3.1 Market Trend Based Strategies

40.3.2 Competitor Strategies

41. Appendix

41.1. Abbreviations

41.2. Currencies

41.3. Historic And Forecast Inflation Rates

41.4. Research Inquiries

41.5. The Business Research Company

41.6. Copyright And Disclaimer

List Of Tables

Table 1: Global Checkpoint Inhibitor Refractory Cancer Market, Overview Of Key Products - Product Examples

Table 2: Global Checkpoint Inhibitor Refractory Cancer Market Attractiveness, Factor-Wise Evaluation

Table 3: Global Checkpoint Inhibitor Refractory Cancer Market, Supply Chain Analysis

Table 4: Global Checkpoint Inhibitor Refractory Cancer Market, Major Raw Material Providers

Table 5: Global Checkpoint Inhibitor Refractory Cancer Market, Major Resource Providers

Table 6: Global Checkpoint Inhibitor Refractory Cancer Market, Major Manufacturers (Suppliers)

Table 7: Global Checkpoint Inhibitor Refractory Cancer Market, Major Distributors And Channel Partners

Table 8: Global Checkpoint Inhibitor Refractory Cancer Market, Key Technologies & Future Trends

Table 9: Global Checkpoint Inhibitor Refractory Cancer Market, Major Trends

Table 10: Global Checkpoint Inhibitor Refractory Cancer Market, Major End Users

Table 11: Global Checkpoint Inhibitor Refractory Cancer Market, PESTEL (Political, Economic, Social, Technology, Environmental and Legal) Analysis

Table 12: Global Checkpoint Inhibitor Refractory Cancer Historic Market Growth, 2020-2025, $ Billion

Table 13: Global Checkpoint Inhibitor Refractory Cancer Forecast Market Growth, 2025-2030F, 2035F, $ Billion

Table 14: Global Checkpoint Inhibitor Refractory Cancer Market - TAM, US$ Billion, 2025

Table 15: Global Checkpoint Inhibitor Refractory Cancer Market, Segmentation By Therapy, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 16: Global Checkpoint Inhibitor Refractory Cancer Market, Segmentation By Cancer Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 17: Global Checkpoint Inhibitor Refractory Cancer Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 18: Global Checkpoint Inhibitor Refractory Cancer Market, Segmentation By Administration Route, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 19: Global Checkpoint Inhibitor Refractory Cancer Market, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 20: Global Checkpoint Inhibitor Refractory Cancer Market, Sub-Segmentation Of Immune Checkpoint Inhibitors, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 21: Global Checkpoint Inhibitor Refractory Cancer Market, Sub-Segmentation Of Combination Therapies, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 22: Global Checkpoint Inhibitor Refractory Cancer Market, Sub-Segmentation Of Targeted Therapies, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 23: Global Checkpoint Inhibitor Refractory Cancer Market, Split By Region, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 24: Global Checkpoint Inhibitor Refractory Cancer Market, Split By Country, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 25: Asia-Pacific, Checkpoint Inhibitor Refractory Cancer Market, Segmentation By Therapy, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 26: Asia-Pacific, Checkpoint Inhibitor Refractory Cancer Market, Segmentation By Cancer Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 27: Asia-Pacific, Checkpoint Inhibitor Refractory Cancer Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 28: China, Checkpoint Inhibitor Refractory Cancer Market, Segmentation By Therapy, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 29: China, Checkpoint Inhibitor Refractory Cancer Market, Segmentation By Cancer Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 30: China, Checkpoint Inhibitor Refractory Cancer Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 31: India, Checkpoint Inhibitor Refractory Cancer Market, Segmentation By Therapy, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 32: India, Checkpoint Inhibitor Refractory Cancer Market, Segmentation By Cancer Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 33: India, Checkpoint Inhibitor Refractory Cancer Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 34: Japan, Checkpoint Inhibitor Refractory Cancer Market, Segmentation By Therapy, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 35: Japan, Checkpoint Inhibitor Refractory Cancer Market, Segmentation By Cancer Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 36: Japan, Checkpoint Inhibitor Refractory Cancer Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 37: Australia, Checkpoint Inhibitor Refractory Cancer Market, Segmentation By Therapy, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 38: Australia, Checkpoint Inhibitor Refractory Cancer Market, Segmentation By Cancer Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 39: Australia, Checkpoint Inhibitor Refractory Cancer Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 40: Indonesia, Checkpoint Inhibitor Refractory Cancer Market, Segmentation By Therapy, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 41: Indonesia, Checkpoint Inhibitor Refractory Cancer Market, Segmentation By Cancer Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 42: Indonesia, Checkpoint Inhibitor Refractory Cancer Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 43: South Korea, Checkpoint Inhibitor Refractory Cancer Market, Segmentation By Therapy, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 44: South Korea, Checkpoint Inhibitor Refractory Cancer Market, Segmentation By Cancer Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 45: South Korea, Checkpoint Inhibitor Refractory Cancer Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 46: Taiwan, Checkpoint Inhibitor Refractory Cancer Market, Segmentation By Therapy, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 47: Taiwan, Checkpoint Inhibitor Refractory Cancer Market, Segmentation By Cancer Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 48: Taiwan, Checkpoint Inhibitor Refractory Cancer Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 49: South East Asia, Checkpoint Inhibitor Refractory Cancer Market, Segmentation By Therapy, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 50: South East Asia, Checkpoint Inhibitor Refractory Cancer Market, Segmentation By Cancer Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 51: South East Asia, Checkpoint Inhibitor Refractory Cancer Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 52: Western Europe, Checkpoint Inhibitor Refractory Cancer Market, Segmentation By Therapy, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 53: Western Europe, Checkpoint Inhibitor Refractory Cancer Market, Segmentation By Cancer Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 54: Western Europe, Checkpoint Inhibitor Refractory Cancer Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 55: UK, Checkpoint Inhibitor Refractory Cancer Market, Segmentation By Therapy, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 56: UK, Checkpoint Inhibitor Refractory Cancer Market, Segmentation By Cancer Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 57: UK, Checkpoint Inhibitor Refractory Cancer Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 58: Germany, Checkpoint Inhibitor Refractory Cancer Market, Segmentation By Therapy, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 59: Germany, Checkpoint Inhibitor Refractory Cancer Market, Segmentation By Cancer Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 60: Germany, Checkpoint Inhibitor Refractory Cancer Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 61: France, Checkpoint Inhibitor Refractory Cancer Market, Segmentation By Therapy, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 62: France, Checkpoint Inhibitor Refractory Cancer Market, Segmentation By Cancer Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 63: France, Checkpoint Inhibitor Refractory Cancer Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 64: Italy, Checkpoint Inhibitor Refractory Cancer Market, Segmentation By Therapy, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 65: Italy, Checkpoint Inhibitor Refractory Cancer Market, Segmentation By Cancer Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 66: Italy, Checkpoint Inhibitor Refractory Cancer Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 67: Spain, Checkpoint Inhibitor Refractory Cancer Market, Segmentation By Therapy, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 68: Spain, Checkpoint Inhibitor Refractory Cancer Market, Segmentation By Cancer Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 69: Spain, Checkpoint Inhibitor Refractory Cancer Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 70: Eastern Europe, Checkpoint Inhibitor Refractory Cancer Market, Segmentation By Therapy, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 71: Eastern Europe, Checkpoint Inhibitor Refractory Cancer Market, Segmentation By Cancer Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 72: Eastern Europe, Checkpoint Inhibitor Refractory Cancer Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 73: Russia, Checkpoint Inhibitor Refractory Cancer Market, Segmentation By Therapy, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 74: Russia, Checkpoint Inhibitor Refractory Cancer Market, Segmentation By Cancer Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 75: Russia, Checkpoint Inhibitor Refractory Cancer Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 76: North America, Checkpoint Inhibitor Refractory Cancer Market, Segmentation By Therapy, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 77: North America, Checkpoint Inhibitor Refractory Cancer Market, Segmentation By Cancer Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 78: North America, Checkpoint Inhibitor Refractory Cancer Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 79: USA, Checkpoint Inhibitor Refractory Cancer Market, Segmentation By Therapy, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 80: USA, Checkpoint Inhibitor Refractory Cancer Market, Segmentation By Cancer Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 81: USA, Checkpoint Inhibitor Refractory Cancer Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 82: Canada, Checkpoint Inhibitor Refractory Cancer Market, Segmentation By Therapy, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 83: Canada, Checkpoint Inhibitor Refractory Cancer Market, Segmentation By Cancer Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 84: Canada, Checkpoint Inhibitor Refractory Cancer Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 85: South America, Checkpoint Inhibitor Refractory Cancer Market, Segmentation By Therapy, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 86: South America, Checkpoint Inhibitor Refractory Cancer Market, Segmentation By Cancer Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 87: South America, Checkpoint Inhibitor Refractory Cancer Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 88: Brazil, Checkpoint Inhibitor Refractory Cancer Market, Segmentation By Therapy, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 89: Brazil, Checkpoint Inhibitor Refractory Cancer Market, Segmentation By Cancer Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 90: Brazil, Checkpoint Inhibitor Refractory Cancer Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 91: Middle East, Checkpoint Inhibitor Refractory Cancer Market, Segmentation By Therapy, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 92: Middle East, Checkpoint Inhibitor Refractory Cancer Market, Segmentation By Cancer Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 93: Middle East, Checkpoint Inhibitor Refractory Cancer Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 94: Africa, Checkpoint Inhibitor Refractory Cancer Market, Segmentation By Therapy, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 95: Africa, Checkpoint Inhibitor Refractory Cancer Market, Segmentation By Cancer Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 96: Africa, Checkpoint Inhibitor Refractory Cancer Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 97: Global Checkpoint Inhibitor Refractory Cancer Key Competitor Estimated Market Shares, 2024, Percentage (%)

Table 98: Global Checkpoint Inhibitor Refractory Cancer Market - Company Scoring Matrix

Table 99: Pfizer Inc. Financial Performance

Table 100: Johnson & Johnson Private Limited Financial Performance

Table 101: Merck & Co. Inc. Financial Performance

Table 102: AbbVie Inc. Financial Performance

Table 103: Novartis International AG Financial Performance

Table 104: Global Checkpoint Inhibitor Refractory Cancer Market, Competitive Benchmarking (In USD Billions)

Table 105: Global Checkpoint Inhibitor Refractory Cancer Market, Competitive Dashboard

Table 106: Global Checkpoint Inhibitor Refractory Cancer Market Size Gain ($ Billion), 2025 – 2030 By Country

Table 107: Global, Checkpoint Inhibitor Refractory Cancer Market Size Gain ($ Billion), Segmentation By Therapy, 2025 – 2030

Table 108: Global, Checkpoint Inhibitor Refractory Cancer Market Size Gain ($ Billion), Segmentation By Cancer Type, 2025 – 2030

Table 109: Global, Checkpoint Inhibitor Refractory Cancer Market Size Gain ($ Billion), Segmentation By Mechanism Of Action, 2025 – 2030

List Of Figures

Figure 1: Global Checkpoint Inhibitor Refractory Cancer Market, Overview Of Key Products - Product Examples

Figure 2: Global Checkpoint Inhibitor Refractory Cancer Market Attractiveness, Factor-Wise Evaluation

Figure 3: Global Checkpoint Inhibitor Refractory Cancer Market, Supply Chain Analysis

Figure 4: Global Checkpoint Inhibitor Refractory Cancer Market, Major Raw Material Providers

Figure 5: Global Checkpoint Inhibitor Refractory Cancer Market, Major Resource Providers

Figure 6: Global Checkpoint Inhibitor Refractory Cancer Market, Major Manufacturers (Suppliers)

Figure 7: Global Checkpoint Inhibitor Refractory Cancer Market, Major Distributors And Channel Partners

Figure 8: Global Checkpoint Inhibitor Refractory Cancer Market, Key Technologies & Future Trends

Figure 9: Global Checkpoint Inhibitor Refractory Cancer Market, Major Trends

Figure 10: Global Checkpoint Inhibitor Refractory Cancer Market, Major End Users

Figure 11: Global Checkpoint Inhibitor Refractory Cancer Market, PESTEL (Political, Economic, Social, Technology, Environmental and Legal) Analysis

Figure 12: Global Checkpoint Inhibitor Refractory Cancer Historic Market Growth, 2020-2025, $ Billion

Figure 13: Global Checkpoint Inhibitor Refractory Cancer Forecast Market Growth, 2025-2030F, 2035F, $ Billion

Figure 14: Global Checkpoint Inhibitor Refractory Cancer Market - TAM, US$ Billion, 2025

Figure 15: Global Checkpoint Inhibitor Refractory Cancer Market, Segmentation By Therapy, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 16: Global Checkpoint Inhibitor Refractory Cancer Market, Segmentation By Cancer Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 17: Global Checkpoint Inhibitor Refractory Cancer Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 18: Global Checkpoint Inhibitor Refractory Cancer Market, Segmentation By Administration Route, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 19: Global Checkpoint Inhibitor Refractory Cancer Market, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 20: Global Checkpoint Inhibitor Refractory Cancer Market, Sub-Segmentation Of Immune Checkpoint Inhibitors, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 21: Global Checkpoint Inhibitor Refractory Cancer Market, Sub-Segmentation Of Combination Therapies, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 22: Global Checkpoint Inhibitor Refractory Cancer Market, Sub-Segmentation Of Targeted Therapies, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 23: Global Checkpoint Inhibitor Refractory Cancer Market, Split By Region, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 24: Global Checkpoint Inhibitor Refractory Cancer Market, Split By Country, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 25: Asia-Pacific, Checkpoint Inhibitor Refractory Cancer Market, Segmentation By Therapy, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 26: Asia-Pacific, Checkpoint Inhibitor Refractory Cancer Market, Segmentation By Cancer Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 27: Asia-Pacific, Checkpoint Inhibitor Refractory Cancer Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 28: China, Checkpoint Inhibitor Refractory Cancer Market, Segmentation By Therapy, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 29: China, Checkpoint Inhibitor Refractory Cancer Market, Segmentation By Cancer Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 30: China, Checkpoint Inhibitor Refractory Cancer Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 31: India, Checkpoint Inhibitor Refractory Cancer Market, Segmentation By Therapy, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 32: India, Checkpoint Inhibitor Refractory Cancer Market, Segmentation By Cancer Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 33: India, Checkpoint Inhibitor Refractory Cancer Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 34: Japan, Checkpoint Inhibitor Refractory Cancer Market, Segmentation By Therapy, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 35: Japan, Checkpoint Inhibitor Refractory Cancer Market, Segmentation By Cancer Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 36: Japan, Checkpoint Inhibitor Refractory Cancer Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 37: Australia, Checkpoint Inhibitor Refractory Cancer Market, Segmentation By Therapy, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 38: Australia, Checkpoint Inhibitor Refractory Cancer Market, Segmentation By Cancer Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 39: Australia, Checkpoint Inhibitor Refractory Cancer Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 40: Indonesia, Checkpoint Inhibitor Refractory Cancer Market, Segmentation By Therapy, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 41: Indonesia, Checkpoint Inhibitor Refractory Cancer Market, Segmentation By Cancer Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 42: Indonesia, Checkpoint Inhibitor Refractory Cancer Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 43: South Korea, Checkpoint Inhibitor Refractory Cancer Market, Segmentation By Therapy, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 44: South Korea, Checkpoint Inhibitor Refractory Cancer Market, Segmentation By Cancer Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 45: South Korea, Checkpoint Inhibitor Refractory Cancer Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 46: Taiwan, Checkpoint Inhibitor Refractory Cancer Market, Segmentation By Therapy, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 47: Taiwan, Checkpoint Inhibitor Refractory Cancer Market, Segmentation By Cancer Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 48: Taiwan, Checkpoint Inhibitor Refractory Cancer Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 49: South East Asia, Checkpoint Inhibitor Refractory Cancer Market, Segmentation By Therapy, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 50: South East Asia, Checkpoint Inhibitor Refractory Cancer Market, Segmentation By Cancer Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 51: South East Asia, Checkpoint Inhibitor Refractory Cancer Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 52: Western Europe, Checkpoint Inhibitor Refractory Cancer Market, Segmentation By Therapy, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 53: Western Europe, Checkpoint Inhibitor Refractory Cancer Market, Segmentation By Cancer Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 54: Western Europe, Checkpoint Inhibitor Refractory Cancer Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 55: UK, Checkpoint Inhibitor Refractory Cancer Market, Segmentation By Therapy, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 56: UK, Checkpoint Inhibitor Refractory Cancer Market, Segmentation By Cancer Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 57: UK, Checkpoint Inhibitor Refractory Cancer Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 58: Germany, Checkpoint Inhibitor Refractory Cancer Market, Segmentation By Therapy, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 59: Germany, Checkpoint Inhibitor Refractory Cancer Market, Segmentation By Cancer Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 60: Germany, Checkpoint Inhibitor Refractory Cancer Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 61: France, Checkpoint Inhibitor Refractory Cancer Market, Segmentation By Therapy, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 62: France, Checkpoint Inhibitor Refractory Cancer Market, Segmentation By Cancer Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 63: France, Checkpoint Inhibitor Refractory Cancer Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 64: Italy, Checkpoint Inhibitor Refractory Cancer Market, Segmentation By Therapy, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 65: Italy, Checkpoint Inhibitor Refractory Cancer Market, Segmentation By Cancer Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 66: Italy, Checkpoint Inhibitor Refractory Cancer Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 67: Spain, Checkpoint Inhibitor Refractory Cancer Market, Segmentation By Therapy, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 68: Spain, Checkpoint Inhibitor Refractory Cancer Market, Segmentation By Cancer Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 69: Spain, Checkpoint Inhibitor Refractory Cancer Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 70: Eastern Europe, Checkpoint Inhibitor Refractory Cancer Market, Segmentation By Therapy, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 71: Eastern Europe, Checkpoint Inhibitor Refractory Cancer Market, Segmentation By Cancer Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 72: Eastern Europe, Checkpoint Inhibitor Refractory Cancer Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 73: Russia, Checkpoint Inhibitor Refractory Cancer Market, Segmentation By Therapy, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 74: Russia, Checkpoint Inhibitor Refractory Cancer Market, Segmentation By Cancer Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 75: Russia, Checkpoint Inhibitor Refractory Cancer Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 76: North America, Checkpoint Inhibitor Refractory Cancer Market, Segmentation By Therapy, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 77: North America, Checkpoint Inhibitor Refractory Cancer Market, Segmentation By Cancer Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 78: North America, Checkpoint Inhibitor Refractory Cancer Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 79: USA, Checkpoint Inhibitor Refractory Cancer Market, Segmentation By Therapy, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 80: USA, Checkpoint Inhibitor Refractory Cancer Market, Segmentation By Cancer Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 81: USA, Checkpoint Inhibitor Refractory Cancer Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 82: Canada, Checkpoint Inhibitor Refractory Cancer Market, Segmentation By Therapy, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 83: Canada, Checkpoint Inhibitor Refractory Cancer Market, Segmentation By Cancer Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 84: Canada, Checkpoint Inhibitor Refractory Cancer Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 85: South America, Checkpoint Inhibitor Refractory Cancer Market, Segmentation By Therapy, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 86: South America, Checkpoint Inhibitor Refractory Cancer Market, Segmentation By Cancer Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 87: South America, Checkpoint Inhibitor Refractory Cancer Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 88: Brazil, Checkpoint Inhibitor Refractory Cancer Market, Segmentation By Therapy, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 89: Brazil, Checkpoint Inhibitor Refractory Cancer Market, Segmentation By Cancer Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 90: Brazil, Checkpoint Inhibitor Refractory Cancer Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 91: Middle East, Checkpoint Inhibitor Refractory Cancer Market, Segmentation By Therapy, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 92: Middle East, Checkpoint Inhibitor Refractory Cancer Market, Segmentation By Cancer Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 93: Middle East, Checkpoint Inhibitor Refractory Cancer Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 94: Africa, Checkpoint Inhibitor Refractory Cancer Market, Segmentation By Therapy, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 95: Africa, Checkpoint Inhibitor Refractory Cancer Market, Segmentation By Cancer Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 96: Africa, Checkpoint Inhibitor Refractory Cancer Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 97: Global Checkpoint Inhibitor Refractory Cancer Key Competitor Estimated Market Shares, 2024, Percentage (%)

Figure 98: Global Checkpoint Inhibitor Refractory Cancer Market - Company Scoring Matrix

Figure 99: Pfizer Inc. Financial Performance

Figure 100: Johnson & Johnson Private Limited Financial Performance

Figure 101: Merck & Co. Inc. Financial Performance

Figure 102: AbbVie Inc. Financial Performance

Figure 103: Novartis International AG Financial Performance

Figure 104: Global Checkpoint Inhibitor Refractory Cancer Market, Competitive Benchmarking (In USD Billions)

Figure 105: Global Checkpoint Inhibitor Refractory Cancer Market, Competitive Dashboard

Figure 106: Global Checkpoint Inhibitor Refractory Cancer Market Size Gain ($ Billion), 2025 – 2030 By Country

Figure 107: Global, Checkpoint Inhibitor Refractory Cancer Market Size Gain ($ Billion), Segmentation By Therapy, 2025 – 2030

Figure 108: Global, Checkpoint Inhibitor Refractory Cancer Market Size Gain ($ Billion), Segmentation By Cancer Type, 2025 – 2030

Figure 109: Global, Checkpoint Inhibitor Refractory Cancer Market Size Gain ($ Billion), Segmentation By Mechanism Of Action, 2025 – 2030

Advanced Therapy Medicinal Products Industry Poised for Rapid Expansion, Projected to Hit $104.43 Billion by 2029

Global Insights: Androgen Deprivation Therapy Market Expected to Surpass $10.49 Billion by 2029

2025 Anti-CD20 Monoclonal Antibodies Market Outlook: Opportunities, Growth Trends, and Strategic Analysis

Future Projections: Anti-D Immunoglobulin Market to Reach $3.34 Billion by 2029 at 6.6% CAGR

Anti-Inflammatory Biologics Market Revenue Outlook: Strategic Insights and Forecast to 2029

CAGR of 10.8% Projected for Anti-Tumor Drugs Market From 2025 to 2029

Future Demand and Leading Companies Shaping the Asthma Disease Market to 2029

Comprehensive Forecast: Asthma Therapeutics Market Share, Growth, and Opportunities Through 2029

Waterproofing Chemicals Market Report 2026 - Global Outlook – By Product (Bitumen, Elastomers, PVC, TPO, EPDM), By Technology (Preformed Membranes, Coatings And LAMS (Liquid Applied Membrane Systems), Integral Systems), ...

Water Infrastructure Repair Technologies Market Report 2026 - Global Outlook – By Product (Flanges, Valves, Fittings, Pipes And Connectors, Couplings), By Repair Technology (Remote Assessment And Monitoring, Open And Cut...

Water Storage Systems Market Report 2026 - Global Outlook – By Material (Steel, Fiberglass, Concrete, Plastic, Other Materials), By Location (Underground, Indoor, Outdoor), By Application (Onsite Water And Wastewater Col...

Waterproof Tapes Market Report 2026 - Global Outlook – By Resin Types (Acrylic, Butyl), By Substrate Types (Plastic, Metal, Other Substrate Types), By End-Use Industry (Building and Construction, Infrastructure and Civil...

Digital Water Solution Market Report 2026 - Global Outlook – By Solutions (Hardware, Software, Services), By Technology (Metering And Customer Management, Network Management, Work And Asset Management, Plant Management, ...

Water Testing Equipment Market Report 2026 - Global Outlook – By Device Type (Stationary Or Bench-Top, Portable), By Test Type (pH Test, Dissolved Oxygen Test, Conductivity Test, Turbidity Test, T.D.C. Tests (Total Disso...

Deionized Water Systems Market Report 2026 - Global Outlook – By Type (Two Bed Deionized Water System, Mixed Bed Deionized Water System, Electrodeionization Water System), By Distribution Channel (Direct Sales, Distribut...

Frequently Asked Questions

How big is the Checkpoint Inhibitor Refractory Cancer Market?

The Checkpoint Inhibitor Refractory Cancer market was valued at $36.69 billion in 2025, increased to $40.97 billion in 2026, and is projected to reach $63.02 billion by 2030.

What is the Checkpoint Inhibitor Refractory Cancer market growth?

The global Checkpoint Inhibitor Refractory Cancer market is expected to grow at a CAGR of 11.4% from 2026 to 2035 to reach $63.02 billion by 2035.

Who are the key players in Checkpoint Inhibitor Refractory Cancer market?

Some Key Players in the Checkpoint Inhibitor Refractory Cancer market Include, Pfizer Inc., Johnson & Johnson Private Limited, Merck & Co. Inc., AbbVie Inc., Novartis International AG, Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca PLC, GlaxoSmithKline Plc, Eli Lilly and Company, Gilead Sciences Inc., Amgen Inc., Regeneron Pharmaceuticals Inc., Eisai Co. Ltd., Exelixis Inc., Exicure Inc., ImmunityBio Inc., ENB Therapeutics Inc., Kartos Therapeutics Inc., Pliant Therapeutics Inc. .

What is the anticipated growth trend for the Checkpoint Inhibitor Refractory Cancer market?

Major trend in this market includes: Technological Advancements And Early-Phase Clinical Data In Checkpoint Inhibitor Refractory Cancer Market. For further insights on this market. request a sample here

Which region has the most growth potential in the Checkpoint Inhibitor Refractory Cancer market?

North America was the largest region in the checkpoint inhibitor refractory cancer market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the checkpoint inhibitor refractory cancer market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.